Early PRRT for Neuroendocrine Tumors: Who Should Get It?
Summary
NETTER-2 found longer progression-free survival with first-line PRRT, but experts differ on which patients should receive it early and which should have it reserved for later. Medscape News Europe
Description from Medscape.
Who is covering this
-
Early PRRT for Neuroendocrine Tumors: Who Should Get It?
NETTER-2 found longer progression-free survival with first-line PRRT, but experts differ on which patients should receive it early and which should have it reserved for later. Medscape News Europe
Comments
Comments need JavaScript.